Bullous pemphigoid treatment review

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 17, 2006, Pages 2403-2411

  Patton, Timothy ^a   Korman, Neil J ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti inflammatory; Bullous pemphigoid; Immunosuppressive

Indexed keywords

ALLOPURINOL; ALUMINUM HYDROXIDE; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BILE ACID SEQUESTRANT; CHLORAMBUCIL; CLOBETASOL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DAPSONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; MAGNESIUM HYDROXIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PREDNISONE; RITUXIMAB; SULFAPYRIDINE; TETRACYCLINE; TETRACYCLINE DERIVATIVE; THIOPURINE METHYLTRANSFERASE; UNINDEXED DRUG; VALACICLOVIR; WARFARIN;

ADD ON THERAPY; AGRANULOCYTOSIS; ALLERGIC REACTION; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ANXIETY; ASEPTIC MENINGITIS; BONE MARROW SUPPRESSION; CANCER RISK; CATARACT; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; COST EFFECTIVENESS ANALYSIS; CYTOPENIA; DERMATOMYOSITIS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG PULSE THERAPY; DRUG RECEPTOR BINDING; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GRAFT VERSUS HOST REACTION; HEMOLYTIC ANEMIA; HEMORRHAGIC CYSTITIS; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCREASED APPETITE; INFECTION; INFECTION RISK; INFECTIOUS COMPLICATION; KIDNEY TUBULE NECROSIS; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; METHEMOGLOBINEMIA; MOOD DISORDER; NEUTROPENIA; PATIENT MONITORING; PEMPHIGOID; PLASMAPHERESIS; PSORIASIS; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOEMBOLISM; THROMBOSIS; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CYCLOPHOSPHAMIDE; EXPERT TESTIMONY; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; PEMPHIGOID, BULLOUS; PLASMAPHERESIS;

EID: 33751585622     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.17.2403     Document Type: Review

References (78)

1. KORMAN NJ: Bullous pemphigoid. The latest in diagnosis, prognosis, and therapy. Arch. Dermatol. (1998) 134:1137-1141.
2. COLBERT RL, ALLEN DM, EASTWOOD D, FAIRLEY JA: Mortality rate of bullous pemphigoid in a US medical center. J. Invest. Dermatol. (2004) 122:1091-1095.
3. STANLEY JR, HAWLEY-NELSON P, YUSPA SH, SHEVACH EM, KATZ SI: Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell (1981) 24:897-903.
4. LABIB RS, ANHALT GJ, PATEL HP, MUTASIM DF, DIAZ LA: Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J. Immunol. (1986) 136:1231-1235.
5. LIU Z, GIUDICE GJ, SWARTZ SJ et al.: The role of complement in experimental bullous pemphigoid. J. Clin. Invest. (1995) 95:1539-1544.
6. DEHORATIUS D, WERTH V: Glucocorticoids in the treatment of bullous diseases. Dermatologic Therapy (2002) 15:298-310.
7. DRENO B, SASSOLAS B, LACOUR P et al.: [Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study]. Ann. Dermatol. Venereol. (1993) 120:518-521.
8. MOREL P, GUILLAUME JC: [Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study.] Ann. Dermatol. Venereol. (1984) 111:925-928.
9. BURTON JL, HARMAN RR, PEACHEY RD, WARIN RP: Azathioprine plus prednisone in treatment of pemphigoid. Br. Med. J. (1978) 2:1190-1191.
10. GUILLAUME JC, VAILLANT L, BERNARD P et al.: Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch. Dermatol. (1993) 129:49-53.
11. ROUJEAU JC, GUILLAUME JC, MORELP et al.: Plasma exchange in bullous pemphigoid. Lancet (1984) 2:486-488.
12. FIVENSON DP, BRENEMAN DL, ROSEN GB, HERSH CS, CARDONE S, MUTASIM D: Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch. Dermatol. (1994) 130:753-758.
13. JOLY P, ROUJEAU JC, BENICHOUJ et al.: A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N. Engl. J. Med. (2002) 346:321-327.
14. ARDERN-JONES MR, VENNING VA, WOJNAROWSKA F: Oral and topical corticosteroids in bullous pemphigoid. N. Engl. J. Med. (2002) 347:143-145.
15. SIEGEL J, EAGLSTEIN WH: High-dose methylprednisolone in the treatment of bullous pemphigoid. Arch. Dermatol. (1984) 120:1157-1165.
16. LENNARD L: The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol. (1992) 43:329-339.
17. COLLIE-DUGUID ES, PRITCHARD SC, POWRIE RH et al.: The frequency and distribution of thiopurine methyl transferase alleles in Caucasian and Asian populations. Pharmacogenetics (1999) 9:37-42.
18. SNOWJ L, GIBSON LE: The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch. Dermatol. (1995) 131:193-197.
19. PRESENT DH, MELTZER SJ, KRUMHOLZ MP, WOLKE A, KORELITZ BI: 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann. Intern. Med. (1989) 111:641-649.
20. SPARROW MP, HANDE SA, FRIEDMANS et al.: Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment. Pharmacol. Ther. (2005) 22:441-446.
21. RIVIER G, KHAMASHTA MA, HUGHES GR: Warfarin and azathioprine: a drug interaction does exist. Am. J. Med. (1993) 95:342.
22. GOSSMANN J, KACHEL HG, SCHOEPPE W, SCHEUERMANN EH: Anemia in renal transplant recipients caused by concomitant therapy with azathioprine and angiotensin-converting enzyme inhibitors. Transplantation (1993) 56:585-589.
23. ALLISON AC, EUGUI EM: Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol. Rev. (1993) 136:5-28.
24. SOLLINGER HW, DEIERHOI MH, BELZER FO, DIETHELM AG, KAUFFMAN RS: RS-61443-a Phase I clinical trial and pilot rescue study. Transplantation (1992) 53:428-432.
25. BOHM M, BEISSERT S, SCHWARZ T, METZE D, LUGER T: Bullous pemphigoid treated with mycophenolate mofetil. Lancet (1997) 349:541.
26. NOUSARI HC, GRIFFIN WA, ANHALT GJ: Successful therapy for bullous pemphigoid with mycophenolate mofetil. J. Am. Acad. Dermatol. (1998) 39:497-498.
27. GRUNDMANN-KOLLMANN M, KORTING HC, BEHRENS S et al.: Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J. Am. Acad. Dermatol. (1999) 40:957-960.
28. GRUNDMANN-KOLLMANN M, KASKEL P, LEITER U et al.: Treatment of pemphigus vulgaris and bullous pemphigoid with mycophenolate mofetil monotherapy. Arch. Dermatol. (1999) 135:724-725.
29. LIPSKY JJ: Mycophenolate mofetil. Lancet (1996) 348:1357-1359.
30. ROYER B, ZANETTA G, BERARD M ey al.: A neutropenia suggesting an interaction between valacyclovir and mycophenolate mofetil. Clin. Transplant. (2003) 17:158-161.
31. LANGFORD CA, KLIPPELJH, BALOW JE, JAMES SP, SNELLER MC: Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 1: rheumatologic and renal diseases. Ann. Intern. Med. (1998) 128:1021-1028.
32. LANGFORD CA, KLIPPEL JH, BALOW JE, JAMES SP, SNELLER MC: Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity. Ann. Intern. Med. (1998) 129:49-58.
33. TAIEB A, KLENE C, MALEVILLE J: [Immediate treatment of bullous pemphigus with a corticosteroid-cyclophosphamide combination]. Ann. Dermatol. Venereol. (1986) 113:1223-1229.
34. DAWE RS, NAIDOO DK, FERGUSON J: Severe bullous pemphigoid responsive to pulsed intravenous dexamethasone and oral cyclophosphamide. Br. J. Dermatol. (1997) 137:826-827.
35. ITOH T, HOSOKAWA H, SHIRAI Y, HORIO T: Successful treatment of bullous pemphigoid with pulsed intravenous cyclophosphamide. Br. J. Dermatol. (1996) 134:931-933.
36. DUNN CJ, WAGSTAFF AJ, PERRY CM, PLOSKER GL, GOA KL: Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Drugs (2001) 61:1957-2016.
37. BARTHELEMY H, THIVOLET J, CAMBAZARD F et al.: [Cyclosporin in the treatment of bullous pemphigoid: preliminary study]. Ann. Dermatol. Venereol. (1986) 113:309-313.
38. BOIXEDA JP, SORIA C, MEDINA S, LEDO A: Bullous pemphigoid and psoriasis: treatment with cyclosporine. J. Am. Acad. Dermatol. (1991) 24:152.
39. BIANCHI L, GATTI S, NINI G: Bullous pemphigoid and severe erythrodermic psoriasis: combined low-dose treatment with cyclosporine and systemic steroids. J. Am. Acad. Dermatol. (1992) 27:278.
40. SANDERS S, HARISDANGKUL V: Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am. J. Med. Sci (2002) 323:190-193.
41. NOUSARI HC, ANHALT GJ: Bullous pemphigoid treated with leflunomide: a novel immunomodulatory agent. Arch. Dermatol. (2000) 136:1204-1205.
42. ALBERTS DS, CHANG SY, CHEN HS, LARCOM BJ, JONES SE: Pharmacokinetics and metabolism of chlorambucil in man: a preliminary report. Cancer Treat. Rev. (1979) 6(Suppl.):9-17.
43. MILLIGAN A, HUTCHINSON PE: The use of chlorambucil in the treatment of bullous pemphigoid. J. Am. Acad. Dermatol. (1990) 22:796-801.
44. SEIDENFELD AM, SMYTHE HA, OGRYZLO MA, UROWITZ MB, DOTTEN DA: Acute leukemia in rheumatoid arthritis treated with cytotoxic agents. J. Rheumatol. (1976) 3:295-304.
45. OLSEN EA: The pharmacology of methotrexate. J. Am. Acad. Dermatol. (1991) 25:306-318.
46. HEILBORN JD, STAHLE-BACKDAHL M, ALBERTIONI F, VASSILAKI I, PETERSON C, STEPHANSSON E: Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J. Am. Acad. Dermatol. (1999) 40:741-749.
47. DEREURE O, BESSIS D, GUILLOT B, GUILHOU JJ: Treatment of bullous pemphigoid by low-dose methotrexate associated with short-term potent topical steroids: an open prospective study of 18 cases. Arch. Dermatol. (2002) 138:1255-1256.
48. WHITTLE SL, HUGHES RA: Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (2004) 43:267-271.
49. SAGO J: Dapsone. Dermatologic Therapy (2002) 15:340-351.
50. PERSON JR. ROGERS RS III: Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch. Dermatol. (1977) 113:610-615.
51. VENNING VA, MILLARD PR, WOJNAROWSKA F: Dapsone as first line therapy for bullous pemphigoid. Br. J. Dermatol. (1989) 120:83-92.
52. BOUSCARAT F, CHOSIDOW O, PICARD-DAHAN C et al.: Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J. Am. Acad. Dermatol. (1996) 34:683-684.
53. ORION E, MATZ H, WOLF R: The life-threatening complications of dermatologic therapies. Clin. Dermatol. (2005) 23:182-192.
54. HUMBERT P, TREFFEL P, CHAPUIS JF, BUCHET S, DERANCOURT C, AGACHE P: The tetracyclines in dermatology. J. Am. Acad. Dermatol. (1991) 25:691-697.
55. LOO W J, KIRTSCHIG G, F WOJNAROWSKA: Minocycline as a therapeutic option in bullous pemphigoid. Clin. Exp. Dermatol. (2001) 26:376-379.
56. EGAN CA, MEADOWS KP, ZONE JJ: Plasmapheresis as a steroid saving procedure in bullous pemphigoid. Int. J. Dermatol. (2000) 39:230-235.
57. CHERIN P, PELLETIER S, TEIXEIRA A et al.: Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. (2002) 46:467-474.
58. DALAKAS MC: The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol. Ther. (2004) 102:177-193.
59. RUETTER A, LUGER TA: Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view. Am. J. Clin. Dermatol. (2004) 5:153-160.
60. QI M, SCHIFFERLI JA: Inhibition of complement activation by intravenous immunoglobulins. Arthritis Rheum. (1995) 38:146.
61. YU Z, LENNON VA: Mechanism of Intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N. Engl. J. Med. (1999) 340:227-228.
62. GODARD W, ROUJEAU JC, GUILLOT B, ANDRE C, RIFLE G: Bullous pemphigoid and intravenous gammaglobulin. Ann. Intern. Med. (1985) 103:964-965.
63. TAPPEINER G, STEINER A: High-dosage Intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid. J. Am. Acad. Dermatol. (1989) 20:684-685.
64. BECKERS RC, BRAND A, VERMEER BJ, BOOM BW: Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br. J. Dermatol. (1995) 133:289-293.
65. HARMAN KE, BLACK MM: High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br. J. Dermatol. (1999) 140:865-874.
66. AHMED AR: Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J. Am. Acad. Dermatol. (2001) 45:825-835.
67. WETTER DA, DAVIS MD, YIANNIAS JA et al.: Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin. Proc. (2005) 80:41-47.
68. SCHMIDT E, HUNZELMANN N, ZILLIKENS D, BROCKER EB, GOEBELER M: Rituximab in refractory autoimmune bullous diseases. Clin. Exp. Dermatol. (2006) 31:503-508.
69. SZABOLCS P, REESE M, YANCEY KB, HALL RP, KURTZBERG J: Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant. (2002) 30:327-329.
70. MOCKENHAUPT M, GROSBER M, NORGANER J: Daclizumab: a novel therapeutic option in severe bullous pemphigoid. Acta Derm. Venereol. (2005) 85:65-66.
71. LEE JJ, DOWNHAM TF II: Furosemide-induced bullous pemphigoid: case report and review of literature. J. Drugs Dermatol. (2006) 5:562-564.
72. FERRIS LK, JUKIC D, ENGLISH JC III, ZIRWAS MJ: Drug-induced bullous pemphigoid caused by a generic Canadian medication obtained over the internet. Arch. Dermatol. (2005) 141:1474-1476.
73. AKSAKAL BA, OZSOY E, ARNAVUT O, ALI GURER M: Oral terbinafine-induced bullous pemphigoid. Ann. Pharmacother. (2003) 37:1625-1627.
74. VENNING VA, WOJNAROWSKA F: Lack of predictive factors for the clinical course of bullous pemphigoid. J. Am. Acad. Dermatol. (1992) 26:585-589.
75. ROUJEAU JC, LOK C, BASTUJI-GARIN S, MHALLA S, ENGINGER V, BERNARD P: High risk of death in elderly patients with extensive bullous pemphigoid. Arch. Dermatol. (1998) 134:465-469.
76. RZANY B, PARTSCHT K, JUNG M, KIPPES W et al.: Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch. Dermatol. (2002) 138:903-908.
77. KHUMALO N, KIRTSCHIG G, MIDDLETON P, HOLLIS S, WOJNAROWSKA F, MURRELL D: Interventions for bullous pemphigoid. Cochrane Database Syst. Rev. (2005) 3:CD002292.
78. MARICIC M: Glucocorticoid-induced osteoporosis: treatment options and guidelines. Curr. Osteoporos. Rep. (2005) 3:25-29.